RG6289 placebo

Preclinical

RG6289 placebo is one of 2 therapeutic programs targeting Autosomal Dominant Alzheimers Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Autosomal Dominant Alzheimers DiseaseRecruiting

Autosomal Dominant Alzheimers DiseasePreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Autosomal Dominant Alzheimers Disease

#DrugCompanyPhaseTrials

Kisunla

Eli Lilly

Preclinical

1 2

RG6289 placebo

BBanner Health

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

PreclinicalRecruiting

Autosomal Dominant Alzheimers Disease

NCT06996730

Clinical

Trials by Indication[1]

Autosomal Dominant Alzheimers Disease1 trial

A Double-Blind, Placebo-Controlled, Double-Dummy Study of Donanemab and RG6289 in PSEN1 E280A Mutation Carriers, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Donanemab, RG6289, or the Combination of Donanemab and RG6289, in the Treatment of Autosomal-Dominant Alzheimer's Disease

Recruiting·BBanner Health·Preclinical·NCT06996730·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RG6289 placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for RG6289 placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Banner Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: BBanner Health

RG6289 placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Autosomal Dominant Alzheimers Disease1 trial

References

Drug Info

Quick Facts

Related News